HRP20131023T1 - Soli bis(tio-hidrazid amida) za lijeäśenje raka - Google Patents

Soli bis(tio-hidrazid amida) za lijeäśenje raka Download PDF

Info

Publication number
HRP20131023T1
HRP20131023T1 HRP20131023TT HRP20131023T HRP20131023T1 HR P20131023 T1 HRP20131023 T1 HR P20131023T1 HR P20131023T T HRP20131023T T HR P20131023TT HR P20131023 T HRP20131023 T HR P20131023T HR P20131023 T1 HRP20131023 T1 HR P20131023T1
Authority
HR
Croatia
Prior art keywords
methyl
thio
compound
cancer
bis
Prior art date
Application number
HRP20131023TT
Other languages
English (en)
Croatian (hr)
Inventor
Elena Kostik
Farid Vaghefi
Guiqing Liang
Keizo Koya
Lijun Sun
Noriaki Tatsuta
Shoujun Chen
Takayo Inoue
Zhi-Qiang Xia
Original Assignee
Synta Pharmaceuticals Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synta Pharmaceuticals Corp. filed Critical Synta Pharmaceuticals Corp.
Publication of HRP20131023T1 publication Critical patent/HRP20131023T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/38—Amides of thiocarboxylic acids
    • C07C327/56—Amides of thiocarboxylic acids having nitrogen atoms of thiocarboxamide groups further bound to another hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
HRP20131023TT 2004-06-23 2005-06-20 Soli bis(tio-hidrazid amida) za lijeäśenje raka HRP20131023T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58259604P 2004-06-23 2004-06-23
US68136805P 2005-05-16 2005-05-16
PCT/US2005/021642 WO2006009940A1 (en) 2004-06-23 2005-06-20 Bis(thio-hydrazide amide) salts for treatment of cancers

Publications (1)

Publication Number Publication Date
HRP20131023T1 true HRP20131023T1 (hr) 2013-12-06

Family

ID=34993190

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20131023TT HRP20131023T1 (hr) 2004-06-23 2005-06-20 Soli bis(tio-hidrazid amida) za lijeäśenje raka

Country Status (21)

Country Link
US (5) US7385084B2 (enExample)
EP (2) EP1781604B1 (enExample)
JP (1) JP5362986B2 (enExample)
KR (1) KR101313027B1 (enExample)
CN (1) CN1993318B (enExample)
AU (1) AU2005265202B2 (enExample)
BR (1) BRPI0512526A (enExample)
CA (1) CA2570698C (enExample)
DK (1) DK1781604T3 (enExample)
ES (1) ES2430373T3 (enExample)
HR (1) HRP20131023T1 (enExample)
IL (1) IL179632A (enExample)
ME (1) ME01644B (enExample)
NO (1) NO20070378L (enExample)
NZ (1) NZ552159A (enExample)
PL (1) PL1781604T3 (enExample)
PT (1) PT1781604E (enExample)
RS (1) RS52999B (enExample)
RU (2) RU2406722C2 (enExample)
TW (1) TWI389684B (enExample)
WO (1) WO2006009940A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI332943B (en) 2001-07-10 2010-11-11 Synta Pharmaceuticals Corp Taxol enhancer compounds
TWI252847B (en) * 2001-07-10 2006-04-11 Synta Pharmaceuticals Corp Synthesis of taxol enhancers
TWI297335B (en) 2001-07-10 2008-06-01 Synta Pharmaceuticals Corp Taxol enhancer compounds
TWI330079B (en) 2003-01-15 2010-09-11 Synta Pharmaceuticals Corp Treatment for cancers
ES2430373T3 (es) 2004-06-23 2013-11-20 Synta Pharmaceuticals Corp. Sales de bis(tio-hidrazida amida) para tratamiento de cánceres
AU2005306471B2 (en) 2004-11-19 2009-12-17 Synta Pharmaceuticals Corp. Bis(thio-hydrazide amides) for increasing Hsp70 expression
WO2006113695A1 (en) 2005-04-15 2006-10-26 Synta Pharmaceuticals Corp. Combination cancer therapy with bis(thiohydrazide) amide compounds
AU2006236534A1 (en) * 2005-04-15 2006-10-26 Synta Pharmaceuticals Corp. Methods of increasing natural killer cell activity for therapy
NZ563124A (en) * 2005-05-16 2010-12-24 Synta Pharmaceuticals Corp Synthesis of bis(thio-hydrazide amide) salts
JP2009504740A (ja) * 2005-08-16 2009-02-05 シンタ ファーマシューティカルズ コーポレーション ビス（チオ−ヒドラジドアミド）製剤
US20100310587A1 (en) * 2005-08-29 2010-12-09 Academia Sinica Immunomodulatory compositions
GB0607950D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
WO2008024303A2 (en) * 2006-08-21 2008-02-28 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
US20100068174A1 (en) * 2006-08-21 2010-03-18 Synta Pharmaceuticals Corp. Combination with bis (thiohydrazide amides) for treating cancer
JP2010501563A (ja) * 2006-08-21 2010-01-21 シンタ ファーマシューティカルズ コーポレーション 増殖性障害を治療するための化合物
EP2061451A2 (en) * 2006-08-21 2009-05-27 Synta Pharmaceuticals Corporation Bis(thiohydrazide amides) for treating melanoma
JP2010501559A (ja) * 2006-08-21 2010-01-21 シンタ ファーマシューティカルズ コーポレーション 黒色腫の再発を予防するまたは遅らせるのに使用するためのビス（チオヒドラジドアミド）
EP2076254A2 (en) * 2006-08-31 2009-07-08 Synta Pharmaceuticals Corporation Combination with bis(thiohydrazide amides) for treating cancer
US9498528B2 (en) * 2006-09-13 2016-11-22 Genzyme Corporation Treatment of multiple sclerosis (MS)
US7645904B2 (en) 2006-09-15 2010-01-12 Synta Pharmaceuticals Corp. Purification of bis(thiohydrazide amides)
US8618170B2 (en) * 2007-11-09 2013-12-31 Synta Pharmaceuticals Corp. Oral formulations of bis(thiohydrazide amides)
US8581004B2 (en) 2008-02-21 2013-11-12 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
WO2009123704A2 (en) * 2008-03-31 2009-10-08 Synta Pharmaceuticals Corp. Process for preparing bis(thiohydrazide amides)
JP2012506444A (ja) 2008-10-22 2012-03-15 シンタ ファーマシューティカルズ コーポレーション ビス［チオヒドラジドアミド］化合物の遷移金属錯体
WO2010048284A1 (en) 2008-10-22 2010-04-29 Synta Pharmaceuticals Corp. Transition metal complexes of bis[thiohydrazide amide] compounds
US8525776B2 (en) * 2008-10-27 2013-09-03 Lenovo (Singapore) Pte. Ltd Techniques for controlling operation of a device with a virtual touchscreen
JP5631327B2 (ja) 2008-12-01 2014-11-26 シンタ ファーマシューティカルズ コーポレーション 増殖性障害を治療するための化合物
RU2400471C1 (ru) * 2009-04-30 2010-09-27 Учреждение Российской академии наук Институт органической химии им. Н.Д. Зелинского РАН (ИОХ РАН) N-замещенные производные тиогидразидов оксаминовых кислот, способ их получения и их использование
WO2011069159A2 (en) * 2009-12-04 2011-06-09 Synta Pharmaceuticals Corp. Bis[thiohydrazide amide] compounds for treating leukemia
US8815945B2 (en) * 2010-04-20 2014-08-26 Masazumi Nagai Use of bis [thiohydrazide amide] compounds such as elesclomol for treating cancers
JP2013545759A (ja) 2010-11-18 2013-12-26 シンタ ファーマスーティカルズ コーポレーション 低酸素状態に基づくエレスクロモールによる治療に適した被験体の事前選択
EP2776021A1 (en) * 2011-11-10 2014-09-17 Synta Pharmaceuticals Corp. Administration of a bis(thiohydrazide amide) compound for treating cancers
US20130149392A1 (en) 2011-12-12 2013-06-13 Synta Pharmaceuticals Corp. Method of treating non-small cell lung cancer with bis-(thiohydrazide)amide compounds
US20150057357A1 (en) * 2012-01-05 2015-02-26 The Board Of Trustees Of The Leland Stanford Junior University Bis (thiohydrazide amide) compounds for treating cancers

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2097737A5 (en) 1970-07-14 1972-03-03 Berlin Chemie Veb Virustatic 4-substd 1-acylthiosemicarbazides -from carboxylic acid - hydrazide and isothiocyanates or from carboxylic acid chloride and 4-
DE2037257A1 (en) 1970-07-28 1972-02-03 Farbwerke Hoechst AG, vorm. Meister Lucius & Brüning, 6000 Frankfurt Poly-(5-amino-1,3,4-thiadiazol-2-yl) derivs prepn - intermediates for drug and polymer prodn
GB1272920A (en) 1971-03-15 1972-05-03 Berlin Chemie Veb New thiosemicarbazides
US4012360A (en) 1973-12-03 1977-03-15 Ciba-Geigy Corporation Bis-salicyloyl-dicarboxylic acid dihydrazides as stabilizers for polyolefines
JPS5091056A (enExample) 1973-12-17 1975-07-21
US4822777A (en) * 1987-02-27 1989-04-18 Liposome Technology, Inc. Amphotericin B/cholesterol sulfate composition
JP2767241B2 (ja) 1987-04-15 1998-06-18 ロ−ム アンド ハ−ス コンパニ− 殺虫性のｎ−（場合により置換された）−ｎ′−置換−ｎ，ｎ′−ジ置換ヒドラジン
US6013836A (en) 1992-02-28 2000-01-11 Rohm And Haas Company Insecticidal N'-substituted-N,N'-disubstitutedhydrazines
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
CH683965A5 (it) * 1993-02-19 1994-06-30 Limad Marketing Exp & Imp Composti della classe dei ftalidrazidici come sostanza attiva in agenti antinfiammatori ed antitossici.
US5916596A (en) * 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6753006B1 (en) * 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US6537579B1 (en) * 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US6749868B1 (en) * 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6096331A (en) * 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US5665382A (en) * 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of pharmaceutically active agents for in vivo delivery
PT693924E (pt) * 1993-02-22 2004-09-30 American Biosciences Processos para administracao (in vivo) de substancias biologicas e composicoes utilizadas nestes processos
US5840746A (en) * 1993-06-24 1998-11-24 Merck Frosst Canada, Inc. Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
US5523325A (en) 1993-09-09 1996-06-04 Jacobson; Richard M. Amidrazones and their use as pesticides
EP0763014A1 (de) 1994-06-03 1997-03-19 Basf Aktiengesellschaft Carbamoylcarbonsäurehydrazide und ihre verwendung zur bekämpfung von schadpilzen
JP3535177B2 (ja) 1995-09-22 2004-06-07 バイオイメージ・アクティーゼルスカブ 緑色蛍光性タンパクであるｇｆｐの新規な変種
US5739686A (en) * 1996-04-30 1998-04-14 Naughton; Michael J. Electrically insulating cantilever magnetometer with mutually isolated and integrated thermometry, background elimination and null detection
US6235787B1 (en) 1997-06-30 2001-05-22 Hoffmann-La Roche Inc. Hydrazine derivatives
GB9727524D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Synergistic antitumor composition containing a biologically active ureido compound
TW479053B (en) 1998-10-19 2002-03-11 Agro Kanesho Co Ltd Hydrazineoxoacetamide derivatives and pesticides
ES2161594B1 (es) 1998-12-17 2003-04-01 Servier Lab Nuevos derivados de la hidrazida, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
RU2191015C2 (ru) * 1999-11-05 2002-10-20 Общество с ограниченной ответственностью "Центр бифункциональных иммуномодуляторов" Динатриевая соль n-(6-метил-2,4-диоксо-1,2,3,4-тетрагидро-5h-пиримидинсульфон)-n'- изоникотиноилгидразида, проявляющая антимикробную и иммунотропную активность, и лекарственное средство на ее основе
US6322303B1 (en) 2000-05-12 2001-11-27 David M. John Dunnage bag and method of making same
EP1164126A1 (de) 2000-06-16 2001-12-19 Basf Aktiengesellschaft Salicylsäurehydrazid-Derivate, Verfahren und Zwischenprodukte zu ihrer Herstellung, sie enthaltende Mittel und ihre Verwendung zur Bekämpfung von Schadpilzen
US6365745B1 (en) 2000-07-14 2002-04-02 Sumika Fine Chemicals Co., Ltd. Method for producing hydrazine derivative
CA2435829A1 (en) 2001-01-25 2002-08-01 Guilford Pharmaceuticals Inc. Trisubstituted carbocyclic cyclophilin binding compounds and their use
CA2445967A1 (en) * 2001-05-01 2002-11-07 Abbott Laboratories Compositions comprising lopinavir and methods for enhancing the bioavailability of pharmaceutical agents
US20040235813A1 (en) 2001-05-03 2004-11-25 Erich Wanker Compounds that inhibit hsp90 and stimulate hsp70 and hsp40, useful in the prevention or treatment of diseases associated with protein aggregation and amyloid formation
US6602907B1 (en) 2001-06-08 2003-08-05 University Of Central Florida Treatment of breast cancer
TWI297335B (en) * 2001-07-10 2008-06-01 Synta Pharmaceuticals Corp Taxol enhancer compounds
TWI252847B (en) 2001-07-10 2006-04-11 Synta Pharmaceuticals Corp Synthesis of taxol enhancers
US6924312B2 (en) 2001-07-10 2005-08-02 Synta Pharmaceuticals Corp. Taxol enhancer compounds
TWI332943B (en) 2001-07-10 2010-11-11 Synta Pharmaceuticals Corp Taxol enhancer compounds
AU2002361345B8 (en) * 2001-11-28 2008-06-26 Ipsen Pharma S.A.S. 5-sulphanyl-4H-1,2,4-triazole derivatives and their use as medicine
TW200408407A (en) 2001-11-30 2004-06-01 Dana Farber Cancer Inst Inc Methods and compositions for modulating the immune system and uses thereof
AU2006228035B2 (en) 2003-01-15 2010-02-18 Synta Pharmaceuticals Corp. Bis (thio-hydrazide amide) compounds for treating multi-drug resistant cancer
TWI330079B (en) 2003-01-15 2010-09-11 Synta Pharmaceuticals Corp Treatment for cancers
EA009919B1 (ru) 2003-02-11 2008-04-28 Вернэлис (Кембридж) Лимитед Соединения изоксазола
KR100575251B1 (ko) 2003-03-03 2006-05-02 재단법인서울대학교산학협력재단 ｐ38／ＪＴＶ－1을 유효성분으로 하는 암 치료용 약학적조성물 및 암 치료용 약학적 조성물의 스크리닝 방법
KR100486693B1 (ko) * 2003-03-17 2005-05-03 삼성전자주식회사 금속 매립 방법
EP1493445A1 (en) 2003-07-04 2005-01-05 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibition of stress-induced ligand-dependent EGFR activation
TWI339206B (en) 2003-09-04 2011-03-21 Vertex Pharma Compositions useful as inhibitors of protein kinases
KR100544347B1 (ko) * 2003-12-11 2006-01-23 한국생명공학연구원 디아릴이소옥사졸계 화합물을 유효성분으로 함유하는 암 예방 및 치료용 약학적 조성물
AU2005230867A1 (en) 2004-03-26 2005-10-20 Amphora Discovery Corporation Certain triazole-based compounds, compositions, and uses thereof
US7011923B2 (en) * 2004-04-07 2006-03-14 International Business Machines Corporation Negative photoresist and method of using thereof
ES2430373T3 (es) * 2004-06-23 2013-11-20 Synta Pharmaceuticals Corp. Sales de bis(tio-hidrazida amida) para tratamiento de cánceres
US20060142393A1 (en) 2004-09-16 2006-06-29 Sherman Matthew L Bis(thio-hydrazide amides) for treatment of hyperplasia
AU2005306471B2 (en) 2004-11-19 2009-12-17 Synta Pharmaceuticals Corp. Bis(thio-hydrazide amides) for increasing Hsp70 expression
US20060167106A1 (en) * 2004-11-19 2006-07-27 Mei Zhang Compounds acting at the centrosome
CN101142198B (zh) 2005-02-17 2012-10-31 辛塔制药公司 用于治疗疾病的异*唑坎布雷它斯丁衍生物
AU2006236534A1 (en) 2005-04-15 2006-10-26 Synta Pharmaceuticals Corp. Methods of increasing natural killer cell activity for therapy
WO2006113695A1 (en) 2005-04-15 2006-10-26 Synta Pharmaceuticals Corp. Combination cancer therapy with bis(thiohydrazide) amide compounds
WO2006113493A2 (en) 2005-04-15 2006-10-26 Synta Pharmaceuticals Corp. Methods of determining cancer prognosis via natural killer cell activity
NZ563124A (en) 2005-05-16 2010-12-24 Synta Pharmaceuticals Corp Synthesis of bis(thio-hydrazide amide) salts
JP2009504740A (ja) 2005-08-16 2009-02-05 シンタ ファーマシューティカルズ コーポレーション ビス（チオ−ヒドラジドアミド）製剤
CA2653222A1 (en) 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
AU2007288337B2 (en) 2006-08-21 2012-02-16 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
US20100068174A1 (en) 2006-08-21 2010-03-18 Synta Pharmaceuticals Corp. Combination with bis (thiohydrazide amides) for treating cancer
WO2008024298A1 (en) 2006-08-21 2008-02-28 Synta Pharmaceuticals Corp. Bis(thiohydrazide amides) for inhibiting angiogenesis
WO2008024303A2 (en) 2006-08-21 2008-02-28 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
EP2061451A2 (en) 2006-08-21 2009-05-27 Synta Pharmaceuticals Corporation Bis(thiohydrazide amides) for treating melanoma
JP2010501559A (ja) 2006-08-21 2010-01-21 シンタ ファーマシューティカルズ コーポレーション 黒色腫の再発を予防するまたは遅らせるのに使用するためのビス（チオヒドラジドアミド）
EP2076254A2 (en) 2006-08-31 2009-07-08 Synta Pharmaceuticals Corporation Combination with bis(thiohydrazide amides) for treating cancer
EP2061430A2 (en) 2006-09-11 2009-05-27 Synta Pharmaceuticals Corporation Bis (thiohydrazide amides) formulation
AU2007294752A1 (en) 2006-09-14 2008-03-20 Synta Pharmaceuticals Corp. Compounds for the treatment of angiogenesis
US7645904B2 (en) 2006-09-15 2010-01-12 Synta Pharmaceuticals Corp. Purification of bis(thiohydrazide amides)
WO2008082579A1 (en) 2007-01-03 2008-07-10 Synta Pharmaceuticals Corp. Method for treating cancer
WO2008136976A2 (en) 2007-04-30 2008-11-13 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
TW200922550A (en) 2007-08-07 2009-06-01 Synta Pharmaceuticals Corp Compounds for treating proliferative disorders
US8618170B2 (en) 2007-11-09 2013-12-31 Synta Pharmaceuticals Corp. Oral formulations of bis(thiohydrazide amides)
WO2009073148A2 (en) 2007-11-28 2009-06-11 Synta Pharmaceuticals Corp. Polymorphs of n-malonyl-bis(n'-methyl-n'-thiobenzoylhydrazide)
JP5091056B2 (ja) 2008-08-28 2012-12-05 三甲株式会社 密閉容器の蓋部シール構造

Also Published As

Publication number Publication date
US7579503B2 (en) 2009-08-25
NZ552159A (en) 2009-12-24
KR101313027B1 (ko) 2013-10-02
AU2005265202A1 (en) 2006-01-26
EP2305642A2 (en) 2011-04-06
EP2305642A3 (en) 2011-12-14
US20060135595A1 (en) 2006-06-22
US20090281172A1 (en) 2009-11-12
US7795313B2 (en) 2010-09-14
US20100324143A1 (en) 2010-12-23
RU2010145056A (ru) 2012-05-20
CA2570698C (en) 2013-11-19
TWI389684B (zh) 2013-03-21
HK1104526A1 (en) 2008-01-18
IL179632A0 (en) 2007-05-15
RS52999B (sr) 2014-02-28
US8461208B2 (en) 2013-06-11
PT1781604E (pt) 2013-10-15
RU2007101898A (ru) 2008-07-27
CA2570698A1 (en) 2006-01-26
US8048925B2 (en) 2011-11-01
KR20070029259A (ko) 2007-03-13
EP1781604B1 (en) 2013-08-07
CN1993318B (zh) 2012-10-03
EP1781604A1 (en) 2007-05-09
PL1781604T3 (pl) 2014-01-31
ES2430373T3 (es) 2013-11-20
JP5362986B2 (ja) 2013-12-11
DK1781604T3 (da) 2013-09-16
NO20070378L (no) 2007-03-16
CN1993318A (zh) 2007-07-04
US7385084B2 (en) 2008-06-10
ME01644B (me) 2014-09-20
TW200612895A (en) 2006-05-01
US20120035266A1 (en) 2012-02-09
WO2006009940A1 (en) 2006-01-26
AU2005265202B2 (en) 2009-07-23
US20080269340A1 (en) 2008-10-30
RU2406722C2 (ru) 2010-12-20
IL179632A (en) 2012-08-30
JP2008504264A (ja) 2008-02-14
BRPI0512526A (pt) 2008-03-11

Similar Documents

Publication Publication Date Title
HRP20131023T1 (hr) Soli bis(tio-hidrazid amida) za lijeäśenje raka
Borthakur et al. Recent advances in transition metal diborane (6), diborane (4) and diborene (2) chemistry
JP2008504264A5 (enExample)
CA2737754C (en) Co-crystals of tramadol and nsaids
Haribabu et al. Unprecedented formation of palladium (II)-pyrazole based thiourea from chromone thiosemicarbazone and [PdCl2 (PPh3) 2]: Interaction with biomolecules and apoptosis through mitochondrial signaling pathway
Krylov et al. Metal-free cross-dehydrogenative C–O Coupling of carbonyl compounds with N-hydroxyimides: Unexpected selective behavior of highly reactive free radicals at an elevated temperature
IL187056A (en) Method of Preparation of Bite-Salt (Theo-Drazide Amide)
CN107311846A (zh) 偕二氟乙基取代的二苯乙烯和二苯乙烷类衍生物及其制备方法和应用
WO2019020026A1 (zh) 二氟甲氧基取代的二苯乙烷及反式二苯乙烯衍生物及其制备方法和应用
JP2017528416A5 (enExample)
Qiu et al. A diastereoselective synthesis of cyclopentanones via photocatalytic reductive alkyltrifluoromethylation of ynones
Szczęśniak-Sięga et al. Synthesis and pharmacological evaluation of novel arylpiperazine oxicams derivatives as potent analgesics without ulcerogenicity
Mosaddegh et al. A clean and highly efficient synthesis of 4, 4′-(arylmethylene) bis (3-methyl-1-phenyl-1H-pyrazol-5-ols) using Ce (SO4) 2.4 H2O as heterogeneous catalyst
Yang et al. Base promoted gem-difluoroolefination of alkyl triflones
Zhang et al. Synthesis and antigastric ulcer activity of novel 5-isoproyl-3, 8-dimethylazulene derivatives
Makarov et al. 1, 5-Diaryl-3-oxo-1, 4-pentadienes based on (4-oxopiperidin-1-yl)(aryl) methyl phosphonate scaffold: synthesis and antitumor properties
US8507669B2 (en) Optically active dibenzazepine derivatives
Leyva et al. Microwave-assisted synthesis of substituted fluorophenyl mono-and diazides by SNAr. A fast methodology to prepare photoaffinity labeling and crosslinking reagents
Habibi et al. A new and convenient method for synthesis of barbituric acid derivatives
McReynolds et al. Synthesis of hydrophilic aminooxy linkers and multivalent cores for chemoselective aldehyde/ketone conjugation
Quevedo et al. Role of hydroxyl groups on the aromatic ring in the reactivity and selectivity of the reaction of β-phenylethylamines with non-enolizable aldehydes
Gao et al. Synthesis of a novel series of (E, E)-4, 6-bis (styryl)-2-O-glucopyranosyl-pyrimidines and their potent multidrug resistance (MDR) reversal activity against cancer cells
Teimouri et al. An efficient one-pot method for the synthesis of novel ferrocene–triamide conjugates via pseudo five-component reaction
AL-Suraify et al. RETRACTED ARTICLE: Synthesis and characterization of new compounds derived from 1H-indol-5-ylamine
Bai et al. [BMIM] Cl Catalyzed One‐Pot Synthesis of α‐Aminophosphonate Derivatives Containing a 4‐Phenoxyquinazoline Moiety under Microwave Irradiation